EUVIMEDEUVIMED entdecken
Crossref

Glymphatic enhancement as a therapeutic strategy in Alzheimer’s disease: a comprehensive review of preclinical evidence and translational opportunities

Xin Zhang, Yinuo Niu, Xiaomu Wang, Xiaorui Wang, Wen Li, Zhirong Liu, Hui Xu, Zhongqing Sun, Wen Jiang

Ageing and Neurodegenerative Diseases · 03.07.2026 · 6 (2)

DOI: 10.20517/and.2026.3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ageing and Neurodegenerative Diseases, online erschienen am 03.07.2026. Verfasst von Xin Zhang und 8 weiteren Autor:innen. Die Arbeit nennt 137 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The glymphatic system is a brain-wide waste clearance network responsible for eliminating metabolic byproducts, including amyloid-beta (Aβ) and tau, two major pathological hallmarks of Alzheimer’s disease (AD). This review synthesizes current evidence indicating that glymphatic dysfunction, driven by structural and molecular impairments in meningeal lymphatic vessels, perivascular spaces, and aquaporin-4 (AQP4) channels, plays a critical role in the pathogenesis and progression of AD. Multiple contributing factors, including aging, sleep disturbances, and genetic susceptibility such as apolipoprotein E4 (APOE4), further aggravate glymphatic impairment, thereby promoting Aβ accumulation, neuroinflammation, and cognitive decline. Emerging therapeutic strategies aimed at restoring glymphatic function include pharmacological interventions, such as melatonin, cilostazol, and vascular endothelial growth factor C (VEGF-C), as well as traditional Chinese medicine approaches, including Borneol and Yuanzhi Powder, and neuromodulation-based therapies such as focused ultrasound and electroacupuncture. In addition, lifestyle interventions, particularly physical exercise and sleep optimization, may enhance cerebrospinal fluid (CSF) dynamics and preserve AQP4 polarization, thereby facilitating metabolic clearance. Preclinical studies have demonstrated that these interventions can reduce Aβ and tau deposition, suppress neuroinflammation, and improve cognition. However, substantial clinical validation remains necessary before these findings can be translated into effective therapeutic applications. Collectively, this review highlights the glymphatic system as a promising therapeutic target for AD and provides an integrated perspective linking mechanistic insights with emerging therapeutic strategies.

Zitieren

APA

Zhang, X., Niu, Y., Wang, X., Wang, X., Li, W., Liu, Z., Xu, H., Sun, Z., & Jiang, W. (2026). Glymphatic enhancement as a therapeutic strategy in Alzheimer’s disease: a comprehensive review of preclinical evidence and translational opportunities. Ageing and Neurodegenerative Diseases, 6(2). https://doi.org/10.20517/and.2026.3

Vancouver

Zhang X, Niu Y, Wang X, Wang X, Li W, Liu Z, et al. Glymphatic enhancement as a therapeutic strategy in Alzheimer’s disease: a comprehensive review of preclinical evidence and translational opportunities. Ageing and Neurodegenerative Diseases. 2026;6(2). doi:10.20517/and.2026.3

BibTeX
@article{Zhang2026,
  author = {Zhang, Xin and Niu, Yinuo and Wang, Xiaomu and Wang, Xiaorui and Li, Wen and Liu, Zhirong and Xu, Hui and Sun, Zhongqing and Jiang, Wen},
  title = {Glymphatic enhancement as a therapeutic strategy in Alzheimer’s disease: a comprehensive review of preclinical evidence and translational opportunities},
  journal = {Ageing and Neurodegenerative Diseases},
  year = {2026},
  volume = {6},
  number = {2},
  doi = {10.20517/and.2026.3}
}
Kostenlos starten →